Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLL.L Regulatory News (CLL)

  • There is currently no data for CLL

Trading update

19 Jan 2011 07:00

RNS Number : 6952Z
Cello Group plc
19 January 2011
 



19 January 2011

 

Cello Group plc

Pre-close trading update - year ended 31 December 2010

 

Cello Group plc (AIM: CLL, 'the Group'), the insight and strategic marketing group, today publishes the following pre-close trading update for the year ended 31 December 2010.

 

Summary

 

The Group has experienced strong profit growth backed by strong cash conversion. The Board expects that full-year headline pre-tax profits will be ahead of expectations and net debt will be better than expected at less than £9.0m.

 

Operating performance

 

Research and Consulting

 

The Group's market research and consulting business has experienced a strong second half, with robust like-for-like revenue growth. Operating profits are expected to have risen by more than 20% on a like-for-like annual basis, reflecting continued strong spending patterns from the Group's broad, international blue-chip client base, and improving operating margins.

 

Performance has been particularly strong in the pharmaceutical and health related client sectors, which now constitute the primary area of the Group's research and consulting activity and which operate at a higher margin than the Group's other client sectors.

 

Non-UK revenues are growing faster than UK revenues and now comprise almost half of the Group's research and consulting activity. In particular, the Group's pharmaceutical offering based in the New York office has performed very strongly and is expanding rapidly. In addition, following significant blue-chip client wins in 2010, the Group intends to expand its US West Coast office more aggressively in 2011.

 

As indicated in the Group's interim results, which were announced on 14 September 2010, the Group has incurred an exceptional charge of approximately £0.8m relating to the material reduction of the Group's exposure to public sector client spend. This process is now complete.

 

Notable project wins in the research and consulting area came from our long established blue chip client list and include Nokia, TFL, News International, EBay, MTV, Travis Perkins, Adidas, Kellogg's, KPMG, P&G, HP, RIM, PWC, Pfizer, Novartis, Novo Nordisk, Eurostar, GSK Global, Unilever, 3M, Visa, Wrigleys, BUPA, RBS, Citi and Nestle.

 

Tangible

 

Tangible's developing position in web-based social media research and communications has continued to benefit the network, as well as the Group's overall research offering. Approximately 20% of Tangible's activity is now in the research and consulting area, a transition which the Group anticipates continuing rapidly in 2011.

 

Tangible has delivered a solid result, against the headwind of UK public sector marketing cuts. The Board anticipates that, whilst revenues have declined year on year reflecting the reduction in public sector spend, profits will have grown by more than 10% with improved margins driven by good cost management.

 

International revenues in Tangible have grown in 2010, with some significant new client wins. Tangible is opening an office in Beijing which may also serve as a hub for the research and consulting business. We continue to appraise expansion options in the Asia-Pacific region.

 

Notable new business wins by Tangible came from both the commercial and charity sectors, and include Ben & Jerry's, Dettol, O2, Pfizer, Dove, IFAW, SPX, First Great Western, NHS, Tesco Bank, Cancer Research UK, British Red Cross, Sony, Royal Mail, Scottish & Southern Energy, Sainsbury's Finance, Scottish Government, Nestle Purina, Macmillan Cancer Support, Salvation Army and the Stroke Association.

 

Net debt

 

Net debt for the year end will be better than expected, having fallen below £9.0m, reflecting strong cash flow conversion. The Group's overall debt facilities stand at £17.0m, providing financial flexibility and giving the Group scope to prudently expand as appropriate.

 

Outlook

 

Revenue momentum experienced in the research and consulting business in the last quarter of 2010 means that the Group is carrying forward a healthy pipeline of activity into the first quarter of 2011. At this early stage of the year, the Group is currently trading in line with management's expectations. The Board remains optimistic for the prospects in 2011.

 

The Group expects to announce its preliminary results for the year ended 31 December 2010 on Wednesday 15 March 2011.

 

Enquiries:

 

Cello Group plc

Mark Scott, Chief Executive

020 7812 8460

Mark Bentley, Group Finance Director

Altium

Ben Thorne

020 7484 4040

College Hill

Kay Larsen/Rozi Morris

020 7457 2020

 

 

Notes to Editors

 

Cello is an insight and strategic marketing group. The Group's strategy is to create value for shareholders by building an international research and consulting business able to advise blue-chip clients globally, along with a marketing business capable of delivering world class solutions.

 

Cello has annualised revenue in excess of £125m, annualised operating income in excess of £60m and employs just under 800 professional staff.

 

www.cellogroup.co.uk

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTEAXFPFAPFEFF
Date   Source Headline
5th Jun 20181:24 pmRNSBlock listing Interim Review
29th May 20183:45 pmRNSDirector/PDMR Dealings and Total Voting Rights
9th May 20181:14 pmRNSResult of AGM
9th May 20187:00 amRNSAGM Statement
30th Apr 20182:58 pmRNSTotal Voting Rights
26th Apr 20189:45 amRNSChange of Name
25th Apr 20184:45 pmRNSChange of Name update
23rd Apr 201810:28 amRNSChange of name to Cello Health Group plc
16th Apr 20189:30 amRNSAnnual Report and Notice of AGM
22nd Mar 20187:00 amRNSFinal Results
27th Feb 20183:38 pmRNSTotal Voting Rights
18th Jan 20187:00 amRNSPre Close Trading Statement
23rd Nov 20173:54 pmRNSHolding(s) in Company
31st Oct 201711:16 amRNSTotal Voting Rights
26th Oct 20172:37 pmRNSDirector/PDMR Shareholding
29th Sep 20173:43 pmRNSGrant of Options
27th Sep 20174:59 pmRNSDirector/PDMR Shareholding
22nd Sep 201712:05 pmRNSDirector/PDMR Shareholding
20th Sep 20173:58 pmRNSHolding(s) in Company
20th Sep 201711:52 amRNSAdditional Block Listing of Ordinary Shares
20th Sep 20177:00 amRNSInterim Results
31st Aug 20173:19 pmRNSTotal Voting Rights
31st Jul 20173:06 pmRNSTotal Voting Rights
19th Jul 20177:00 amRNSPre Close Trading Statement
18th Jul 20177:00 amRNSAcquisition of Advantage Healthcare Inc
30th Jun 201712:31 pmRNSTotal Voting Rights
23rd Jun 201712:23 pmRNSHolding(s) in Company
14th Jun 201711:33 amRNSDirector/PDMR Shareholding
31st May 201710:27 amRNSTotal Voting Rights
18th May 20172:13 pmRNSHolding(s) in Company
10th May 20175:18 pmRNSHolding(s) in Company
9th May 20172:55 pmRNSResult of AGM
9th May 20177:00 amRNSAGM Statement
2nd May 20173:15 pmRNSIssue of Equity
13th Apr 20172:40 pmRNSAnnual Report and notice of Annual General Meeting
4th Apr 20175:44 pmRNSBlock listing Interim Review
31st Mar 201710:43 amRNSTotal Voting Rights
28th Mar 20173:03 pmRNSHolding(s) in Company
22nd Mar 20177:00 amRNSPreliminary Results
21st Feb 20171:30 pmRNSHolding(s) in Company
20th Feb 20173:19 pmRNSHolding(s) in Company
20th Feb 20179:29 amRNSTotal Voting Rights
17th Feb 201710:40 amRNSResult of General Meeting
1st Feb 20177:00 amRNSPlacing & Acquisition of Defined Health
19th Jan 20177:00 amRNSPre close trading statement
31st Oct 20163:58 pmRNSTotal Voting Rights
28th Oct 201611:37 amRNSDirector/PDMR Shareholding
12th Oct 20167:00 amRNSDirectorate Change
5th Oct 20164:32 pmRNSDirector/PDMR Shareholding
23rd Sep 20165:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.